This week: New Alzheimer’s drug, emergency preparedness, vaping

Oct 10, 2019

Upstate Medical University is screening people who want to participate in a new, national clinical research study of a treatment for mild to moderate Alzheimer's disease. Called the T2 Protect AD, the study evaluates the drug troriluzole for its ability to protect against, slow down or even improve memory and thinking problems that increase as Alzheimer's progresses.

Dr. Sharon Brangman, chief of the Department of Geriatrics, tells about the study in this week’s “HealthLink on Air.”

Participants must be between the ages of 50 and 85 with a diagnosis of mild to moderate Alzheimer's.  The study will last about a year and require nine medical visits. Each participant starts and ends with a magnetic resonance imaging (MRI) brain scan.

To learn more about the study or to participate, visit t2protect.org or contact the Center of Excellence for Alzheimer's Disease at Upstate by calling 315-464-3285.

Also on this week's show, emergency management coordinator Bradley Marmon goes over preparedness for families. And, Dr. Leslie Kohman talks about the risks of vaping. Tune in this Sunday, October 13 at 6 a.m.  and 9 p.m. for more.